These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 34932791

  • 21. Exogenous iron increases hemoglobin in beta-thalassemic mice.
    Ginzburg YZ, Rybicki AC, Suzuka SM, Hall CB, Breuer W, Cabantchik ZI, Bouhassira EE, Fabry ME, Nagel RL.
    Exp Hematol; 2009 Feb; 37(2):172-83. PubMed ID: 19059700
    [Abstract] [Full Text] [Related]

  • 22. Smad2/3-pathway ligand trap luspatercept enhances erythroid differentiation in murine β-thalassaemia by increasing GATA-1 availability.
    Martinez PA, Li R, Ramanathan HN, Bhasin M, Pearsall RS, Kumar R, Suragani RNVS.
    J Cell Mol Med; 2020 Jun; 24(11):6162-6177. PubMed ID: 32351032
    [Abstract] [Full Text] [Related]

  • 23. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study.
    Pasricha SR, Frazer DM, Bowden DK, Anderson GJ.
    Blood; 2013 Jul 04; 122(1):124-33. PubMed ID: 23656728
    [Abstract] [Full Text] [Related]

  • 24. Treatment of Acquired Sideroblastic Anemias.
    Mangaonkar AA, Patnaik MM.
    Hematol Oncol Clin North Am; 2020 Apr 04; 34(2):401-420. PubMed ID: 32089219
    [Abstract] [Full Text] [Related]

  • 25. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.
    Ginzburg Y, Rivella S.
    Blood; 2011 Oct 20; 118(16):4321-30. PubMed ID: 21768301
    [Abstract] [Full Text] [Related]

  • 26. Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts.
    Mies A, Hermine O, Platzbecker U.
    Curr Hematol Malig Rep; 2016 Dec 20; 11(6):416-424. PubMed ID: 27595736
    [Abstract] [Full Text] [Related]

  • 27. Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult β-thalassemia major.
    Casu C, Chessa R, Liu A, Gupta R, Drakesmith H, Fleming R, Ginzburg YZ, MacDonald B, Rivella S.
    Haematologica; 2020 Jul 20; 105(7):1835-1844. PubMed ID: 31582543
    [Abstract] [Full Text] [Related]

  • 28. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis.
    Suragani RN, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, Davies MV, Alexander MJ, Devine M, Loveday KS, Underwood KW, Grinberg AV, Quisel JD, Chopra R, Pearsall RS, Seehra J, Kumar R.
    Nat Med; 2014 Apr 20; 20(4):408-14. PubMed ID: 24658078
    [Abstract] [Full Text] [Related]

  • 29. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.
    Kautz L, Jung G, Du X, Gabayan V, Chapman J, Nasoff M, Nemeth E, Ganz T.
    Blood; 2015 Oct 22; 126(17):2031-7. PubMed ID: 26276665
    [Abstract] [Full Text] [Related]

  • 30. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.
    Schmidt PJ, Toudjarska I, Sendamarai AK, Racie T, Milstein S, Bettencourt BR, Hettinger J, Bumcrot D, Fleming MD.
    Blood; 2013 Feb 14; 121(7):1200-8. PubMed ID: 23223430
    [Abstract] [Full Text] [Related]

  • 31. Elevated CDKN1A (P21) mediates β-thalassemia erythroid apoptosis, but its loss does not improve β-thalassemic erythropoiesis.
    Liang R, Lin M, Menon V, Qiu J, Menon A, Breda L, Arif T, Rivella S, Ghaffari S.
    Blood Adv; 2023 Nov 28; 7(22):6873-6885. PubMed ID: 37672319
    [Abstract] [Full Text] [Related]

  • 32. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
    Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y.
    Blood; 2014 Aug 07; 124(6):873-81. PubMed ID: 24923296
    [Abstract] [Full Text] [Related]

  • 33. Growth differentiation factor 15 in erythroid health and disease.
    Tanno T, Noel P, Miller JL.
    Curr Opin Hematol; 2010 May 07; 17(3):184-90. PubMed ID: 20182355
    [Abstract] [Full Text] [Related]

  • 34. Decreasing TfR1 expression reverses anemia and hepcidin suppression in β-thalassemic mice.
    Li H, Choesang T, Bao W, Chen H, Feola M, Garcia-Santos D, Li J, Sun S, Follenzi A, Pham P, Liu J, Zhang J, Ponka P, An X, Mohandas N, Fleming RE, Rivella S, Li G, Ginzburg YZ.
    Blood; 2017 Mar 16; 129(11):1514-1526. PubMed ID: 28151426
    [Abstract] [Full Text] [Related]

  • 35. Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model.
    Artuso I, Lidonnici MR, Altamura S, Mandelli G, Pettinato M, Muckenthaler MU, Silvestri L, Ferrari G, Camaschella C, Nai A.
    Blood; 2018 Nov 22; 132(21):2286-2297. PubMed ID: 30209118
    [Abstract] [Full Text] [Related]

  • 36. Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.
    Gardenghi S, Grady RW, Rivella S.
    Hematol Oncol Clin North Am; 2010 Dec 22; 24(6):1089-107. PubMed ID: 21075282
    [Abstract] [Full Text] [Related]

  • 37. Causes and Pathophysiology of Acquired Sideroblastic Anemia.
    Rodriguez-Sevilla JJ, Calvo X, Arenillas L.
    Genes (Basel); 2022 Aug 30; 13(9):. PubMed ID: 36140729
    [Abstract] [Full Text] [Related]

  • 38. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.
    Weizer-Stern O, Adamsky K, Amariglio N, Rachmilewitz E, Breda L, Rivella S, Rechavi G.
    Am J Hematol; 2006 Jul 30; 81(7):479-83. PubMed ID: 16755567
    [Abstract] [Full Text] [Related]

  • 39. A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice.
    Wake M, Palin A, Belot A, Berger M, Lorgouilloux M, Bichon M, Papworth J, Bayliss L, Grimshaw B, Rynkiewicz N, Paterson J, Poindron A, Spearing E, Carter E, Hudson R, Campbell M, Petzer V, Besson-Fournier C, Latour C, Largounez A, Gourbeyre O, Fay A, Coppin H, Roth MP, Theurl I, Germaschewski V, Meynard D.
    Blood Adv; 2024 Apr 23; 8(8):1898-1907. PubMed ID: 38241484
    [Abstract] [Full Text] [Related]

  • 40. Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia.
    Garbowski MW, Ugidos M, Risueño A, Shetty JK, Schwickart M, Hermine O, Porter JB, Thakurta A, Vodala S.
    Am J Hematol; 2024 Feb 23; 99(2):182-192. PubMed ID: 37782758
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.